[go: up one dir, main page]

CN1264377A - 用作p38激酶抑制剂的取代的吡唑化合物 - Google Patents

用作p38激酶抑制剂的取代的吡唑化合物 Download PDF

Info

Publication number
CN1264377A
CN1264377A CN98807369A CN98807369A CN1264377A CN 1264377 A CN1264377 A CN 1264377A CN 98807369 A CN98807369 A CN 98807369A CN 98807369 A CN98807369 A CN 98807369A CN 1264377 A CN1264377 A CN 1264377A
Authority
CN
China
Prior art keywords
pyrazol
methyl
alkyl
pyridine
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98807369A
Other languages
English (en)
Chinese (zh)
Inventor
阿绍克·安南塔纳拉扬
迈克尔·克莱尔
波尔·W·科林斯
约斯·佐夫·克里奇
拉耶什·代弗拉
达尼尔·L·弗灵
力枫·耿
冈纳·J·汉森
弗兰基斯·J·科斯兹克
书远·廖
理查德·A·帕蒂斯
沙希德哈·N·劳
尚·拉·塞尔内斯
迈克尔·S·绍斯
迈克尔·A·斯蒂尔
理查德·M·韦
向东·徐
义·于
伊斯克·克汉纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Publication of CN1264377A publication Critical patent/CN1264377A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN98807369A 1997-05-22 1998-05-22 用作p38激酶抑制剂的取代的吡唑化合物 Pending CN1264377A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4757097P 1997-05-22 1997-05-22
US60/047,570 1997-05-22

Publications (1)

Publication Number Publication Date
CN1264377A true CN1264377A (zh) 2000-08-23

Family

ID=21949743

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98807369A Pending CN1264377A (zh) 1997-05-22 1998-05-22 用作p38激酶抑制剂的取代的吡唑化合物

Country Status (24)

Country Link
EP (1) EP1000055A1 (fr)
JP (1) JP2002508754A (fr)
KR (1) KR20010012854A (fr)
CN (1) CN1264377A (fr)
AP (1) AP1246A (fr)
AU (1) AU754830C (fr)
BG (1) BG64313B1 (fr)
BR (1) BR9809147A (fr)
CA (1) CA2291115A1 (fr)
EA (1) EA003925B1 (fr)
EE (1) EE9900527A (fr)
GE (1) GEP20033053B (fr)
HU (1) HUP0001880A3 (fr)
ID (1) ID22982A (fr)
IL (1) IL132991A (fr)
IS (1) IS5257A (fr)
NO (1) NO995695L (fr)
NZ (1) NZ501112A (fr)
OA (1) OA12981A (fr)
PL (1) PL337020A1 (fr)
SK (1) SK157899A3 (fr)
TR (1) TR200000235T2 (fr)
WO (1) WO1998052940A1 (fr)
ZA (1) ZA984358B (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102066322A (zh) * 2008-04-21 2011-05-18 盐野义制药株式会社 具有npy y5受体拮抗作用的化合物
CN104829536A (zh) * 2015-05-04 2015-08-12 陕西科技大学 一种具抗肿瘤活性的苯基吡唑羧酸类化合物及其合成方法
CN105228626A (zh) * 2013-03-15 2016-01-06 加州生物医学研究所 用于诱导软骨形成的化合物和方法
CN105814024A (zh) * 2013-12-12 2016-07-27 住友化学株式会社 芳族化合物及其用途
CN107848962A (zh) * 2015-05-27 2018-03-27 杏林制药株式会社 脲衍生物或其药理学上可接受的盐
CN112480079A (zh) * 2017-11-08 2021-03-12 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289752B (fr) * 1994-03-11 1996-11-01 Ciba Geigy Ag
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
JP2002502380A (ja) 1997-05-22 2002-01-22 ジー．ディー．サール アンド カンパニー ｐ３８キナーゼ阻害剤としてのピラゾール誘導体
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
JP2002504909A (ja) 1997-06-13 2002-02-12 スミスクライン・ビーチャム・コーポレイション 新規な置換ピラゾールおよびピラゾリン化合物
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6858617B2 (en) 1998-05-26 2005-02-22 Smithkline Beecham Corporation Substituted imidazole compounds
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
WO2000019824A1 (fr) 1998-10-07 2000-04-13 Smithkline Beecham Corporation Nouveau traitement pour la gestion des accidents vasculaires cerebraux
WO2000025791A1 (fr) 1998-11-04 2000-05-11 Smithkline Beecham Corporation Pyrazines substitues pyridin-4-yle ou pyrimidin-4-yle
CA2355075C (fr) 1998-12-16 2009-12-08 Aventis Pharma Limited Acetals heteroaryl-cycliques
US6191147B1 (en) * 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
EP1142890B1 (fr) * 1998-12-25 2005-08-03 Teikoku Hormone Mfg. Co., Ltd. Derives d'aminopyrazole
ATE467620T1 (de) 1999-03-26 2010-05-15 Euro Celtique Sa Arylsubstituierte pyrazole, imidazole, oxazole, thiazole und pyrrole, sowie deren verwendung
JP4627944B2 (ja) * 1999-06-03 2011-02-09 あすか製薬株式会社 置換ピラゾール化合物
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
AR032130A1 (es) * 1999-08-13 2003-10-29 Vertex Pharma Un compuesto inhibidor de quinasas proteicas, una composicion farmaceutica que lo incluye, y un metodo para tratar afecciones con dicho compuesto
WO2001030154A2 (fr) * 1999-10-25 2001-05-03 Basf Aktiengesellschaft Compositions agrochimiques contenant des pyrazols comme principes actifs et leur utilisation comme phytosanitaires a action fongicide
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU1783201A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
AU1782301A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p39 kinase inhibitors
JP2003514899A (ja) 1999-11-23 2003-04-22 スミスクライン・ビーチャム・コーポレイション ＣＳＢＰ／ｐ３８キナーゼ阻害剤としての３，４‐ジヒドロ−（１Ｈ）−キナゾリン−２−オン化合物
US7235551B2 (en) 2000-03-02 2007-06-26 Smithkline Beecham Corporation 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases
JP4911864B2 (ja) 2000-08-14 2012-04-04 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾール
WO2002062792A1 (fr) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Inhibiteur de jnk
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
EP1382603B1 (fr) 2001-04-26 2008-07-23 Eisai R&D Management Co., Ltd. Compose azote a anneaux condenses possedant un groupe pyrazolyle et servant de substituant, et composition medicale le comprenant
DK1397364T3 (da) 2001-05-24 2007-11-26 Lilly Co Eli Hidtil ukendte pyrrolderivater som farmaceutiske midler
RU2277534C2 (ru) * 2001-09-25 2006-06-10 Фармация Корпорейшн Способ получения замещенных пиразолов
US7057049B2 (en) 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
YU30504A (sh) 2001-09-25 2006-08-17 Pharmacia Corporation Postupak za dobijanje supstituisanih pirazola
AU2003237446A1 (en) * 2002-06-05 2003-12-22 Pharmacia Corporation Pyrazole-derivatives as p38 kinase inhibitors
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
AU2003245989A1 (en) 2002-07-09 2004-01-23 Boehringer Ingelheim Pharma Gmbh And Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
AU2003265395A1 (en) 2002-08-14 2004-03-03 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
WO2004026302A1 (fr) * 2002-09-19 2004-04-01 Eli Lilly And Company Procedes relatifs a l'inhibition du tgf-beta par le biais de pyrazoles substitues
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
JPWO2004069824A1 (ja) 2003-02-07 2006-05-25 第一製薬株式会社 ピラゾール誘導体
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
JP4084836B2 (ja) 2004-08-12 2008-04-30 ファイザー・インク ｐ３８ＭＡＰキナーゼインヒビターとしてのトリアゾロピリジニルスルファニル誘導体
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CN101080404B (zh) 2004-12-28 2011-06-08 Aska制药株式会社 嘧啶基异噁唑衍生物
CA2643066A1 (fr) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazoles
JPWO2008001929A1 (ja) * 2006-06-28 2009-12-03 あすか製薬株式会社 炎症性腸疾患の処置剤
US8207203B2 (en) 2006-06-28 2012-06-26 Aska Pharmaceutical Co., Ltd. Pyridylisoxazole derivatives
AU2008215659B2 (en) 2007-02-16 2012-11-01 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
EP1992344A1 (fr) 2007-05-18 2008-11-19 Institut Curie P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3
AU2008277730B2 (en) * 2007-07-13 2013-01-31 Addex Pharma S.A. Pyrazole derivatives as modulators of metabotropic glutamate receptors
TW200927115A (en) 2007-11-16 2009-07-01 Boehringer Ingelheim Int Aryl-and heteroarylcarbonyl derivatives of benzomorphanes and related scaffolds, medicaments containing such compounds and their use
US8765780B2 (en) 2008-05-13 2014-07-01 Boehringer Ingelheim International Gmbh Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use
EA019722B1 (ru) 2008-07-24 2014-05-30 НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. 3,4-диарилпиразолы в качестве ингибиторов протеинкиназ
JP5586605B2 (ja) * 2008-08-25 2014-09-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ノルトロパンのアリール及びヘテロアリールカルボニル誘導体、該化合物を含有する医薬及びその使用
KR20110070885A (ko) * 2008-10-23 2011-06-24 론자 리미티드 치환된 피라졸의 합성 방법
WO2010058858A1 (fr) * 2008-11-21 2010-05-27 ラクオリア創薬株式会社 Nouveau dérivé de pyrazole-3-carboxamide doté d’une activité antagoniste du récepteur 5-ht2b
JP5670440B2 (ja) 2009-06-02 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
EP2440537A1 (fr) 2009-06-11 2012-04-18 Vitae Pharmaceuticals, Inc. Inhibiteurs cycliques de la 11-bêta-hydroxystéroïde déshydrogénase 1 basée sur la structure 1,3-oxazinan-2-one
MX2012002420A (es) * 2009-08-26 2012-06-27 Novartis Ag Compuestos de heteroarilo tetra-sustituidos y su uso como moduladores de mdm2 y/o mdm4.
JO3002B1 (ar) 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
EP2308866A1 (fr) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazoles et leur utilisation comme fongicides
BR112012018358A2 (pt) 2009-12-21 2016-08-09 Bayer Cropscience Ag tienilpiri(mi)dinilazol e seu uso para controlar fungos fitopatogênicos
CA2786509C (fr) 2010-01-27 2016-01-05 Nerviano Medical Sciences S.R.L. Derives sulfonamido des 3,4-diarylpyrazones comme inhibiteurs des proteines kinases
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
WO2011159760A1 (fr) 2010-06-16 2011-12-22 Vitae Pharmaceuticals, Inc. Hétérocycles à 5, 6 et 7 chaînons substitués, médicaments contenant ces composés et leur utilisation
CN103153980B (zh) 2010-08-03 2015-12-16 内尔维安诺医学科学有限公司 吡唑并苯基苯磺酰胺化合物的衍生物及其作为抗肿瘤药的用途
WO2012085721A1 (fr) * 2010-12-20 2012-06-28 Pfizer Inc. Nouveaux composés fusionnés de pyridine en tant qu'inhibiteurs de la caséine kinase
AR086992A1 (es) 2011-06-20 2014-02-05 Bayer Ip Gmbh Tienilpiri(mi)dinilpirazoles
EP2744783A1 (fr) 2011-08-17 2014-06-25 Boehringer Ingelheim International GmbH Dérivés d'indénopyridine
CN104039785A (zh) 2011-10-06 2014-09-10 拜耳知识产权有限责任公司 作为杀真菌剂的杂环基吡(嘧)啶基吡唑
JP6211522B2 (ja) 2011-10-06 2017-10-11 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ヘテロシクリルピリ（ミ）ジニルピラゾール
DE102011115525A1 (de) 2011-10-11 2013-04-11 Boehringer Ingelheim International Gmbh Zweiteilige Flasche mit einem darin angeordneten Trockenmittel
RU2622015C2 (ru) 2011-11-11 2017-06-08 Новартис Аг Способ лечения пролиферативного заболевания
ES3037966T3 (en) 2011-11-23 2025-10-08 Array Biopharma Inc Pharmaceutical formulations
EP3886854A4 (fr) 2018-11-30 2022-07-06 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation
WO2020124397A1 (fr) 2018-12-19 2020-06-25 Inventisbio Shanghai Ltd. Inhibiteurs de kinase src c-terminale
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
CN115210229A (zh) 2020-01-03 2022-10-18 博格有限责任公司 多环酰胺作为治疗癌症的ube2k调节剂
EP3978487A1 (fr) * 2020-09-30 2022-04-06 Origo Biopharma, S.L. Dérivés de 2-(3-pyridine-2-yl-4-quinoline-4-yl-pyrazol-1-yl)-acétamide comme inhibiteurs du récepteur du facteur de croissance transformant bêta i/alk5
CN116916914A (zh) * 2020-12-29 2023-10-20 锐新医药公司 Sos1抑制剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2753659B2 (ja) * 1990-09-03 1998-05-20 株式会社大塚製薬工場 ピラゾール誘導体
US5593992A (en) * 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation
JP3734180B2 (ja) * 1994-12-28 2006-01-11 エーザイ株式会社 新規ピラゾール誘導体

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102066322A (zh) * 2008-04-21 2011-05-18 盐野义制药株式会社 具有npy y5受体拮抗作用的化合物
CN105228626A (zh) * 2013-03-15 2016-01-06 加州生物医学研究所 用于诱导软骨形成的化合物和方法
US10500210B2 (en) 2013-03-15 2019-12-10 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
US11045476B2 (en) 2013-03-15 2021-06-29 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
CN105814024A (zh) * 2013-12-12 2016-07-27 住友化学株式会社 芳族化合物及其用途
CN105814024B (zh) * 2013-12-12 2018-04-17 住友化学株式会社 芳族化合物及其用途
CN104829536A (zh) * 2015-05-04 2015-08-12 陕西科技大学 一种具抗肿瘤活性的苯基吡唑羧酸类化合物及其合成方法
CN104829536B (zh) * 2015-05-04 2017-12-29 陕西科技大学 一种具抗肿瘤活性的苯基吡唑羧酸类化合物及其合成方法
CN107848962A (zh) * 2015-05-27 2018-03-27 杏林制药株式会社 脲衍生物或其药理学上可接受的盐
CN107848962B (zh) * 2015-05-27 2021-04-09 杏林制药株式会社 脲衍生物或其药理学上可接受的盐
CN112480079A (zh) * 2017-11-08 2021-03-12 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
CN112480079B (zh) * 2017-11-08 2022-03-11 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途

Also Published As

Publication number Publication date
TR200000235T2 (tr) 2000-05-22
BG64313B1 (bg) 2004-09-30
EE9900527A (et) 2000-06-15
AU754830B2 (en) 2002-11-28
AU7588398A (en) 1998-12-11
EA199900953A1 (ru) 2000-10-30
IL132991A (en) 2005-11-20
GEP20033053B (en) 2003-08-25
JP2002508754A (ja) 2002-03-19
NO995695L (no) 2000-01-21
HUP0001880A2 (en) 2001-03-28
AP1246A (en) 2004-02-07
CA2291115A1 (fr) 1998-11-26
KR20010012854A (ko) 2001-02-26
BR9809147A (pt) 2000-08-01
EA003925B1 (ru) 2003-10-30
AU754830C (en) 2004-02-12
ZA984358B (en) 1999-05-24
EP1000055A1 (fr) 2000-05-17
SK157899A3 (en) 2000-08-14
NO995695D0 (no) 1999-11-19
ID22982A (id) 1999-12-23
AP9901715A0 (en) 1999-12-31
OA12981A (en) 2006-10-13
BG103964A (en) 2000-08-31
IL132991A0 (en) 2001-03-19
IS5257A (is) 1999-11-19
HUP0001880A3 (en) 2002-03-28
NZ501112A (en) 2002-10-25
PL337020A1 (en) 2000-07-31
WO1998052940A1 (fr) 1998-11-26

Similar Documents

Publication Publication Date Title
CN1264377A (zh) 用作p38激酶抑制剂的取代的吡唑化合物
CN1342157A (zh) 用作ASp38激酶抑制剂的取代吡唑
US6979686B1 (en) Substituted pyrazoles as p38 kinase inhibitors
US7569592B2 (en) Heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
EP1385845B1 (fr) Amines cycliques n-aroyle
CN1809354A (zh) Akt活性抑制剂
US20100184758A1 (en) Beta carboline derivatives as antidiabetic compounds
US20080113967A1 (en) Enzyme modulators and treatments
CN1795184A (zh) 二芳基取代的吡唑类代谢型谷氨酸受体－5调节剂
CN1656079A (zh) 吡唑化合物和含有该化合物的药物组合物
JP2009530233A (ja) Ｐｉ−３キナーゼインヒビターおよびそれらの使用方法
RS60099B1 (sr) Jedinjenja i kompozicije sa nokdaun efektom ili aktivnošću inhibicije hranjenja krvlju kod štetnih insekata
US20120040983A1 (en) Phthalazine Compounds as P38 Map Kinase Modulators and Methods of Use Thereof
CZ411899A3 (cs) Substituované pyrazoly jako inhibitory p38 kinázy, způsob jejich přípravy a farmaceutické kompozice
CN1859912A (zh) Akt活性的抑制剂
HK1115874A (en) 1-[2-(heterocyclyl-aminomethyl)-piperidin-1-yl]-1-(2-methyl-5-phenyl-heterocyclyl)-methanone derivatives and related compounds as orexin-1 antagonists for the treatment of obesity
HK1030211A (en) 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication